Dissolution and precipitation behavior of amorphous solid dispersions

Journal of Pharmaceutical Sciences

Volumn 100, Issue 8, 2011, Pages 3316-3331

  Alonzo, David E ^a,b   Gao, Yi ^b   Zhou, Deliang ^b   Mo, Huaping ^c   Zhang, Geoff G Z ^b   Taylor, Lynne S ^a  

^a PURDUE UNIVERSITY   (United States)

^b ABBOTT LABORATORIES   (United States)

^c PURDUE UNIVERSITY   (United States)

Author keywords

Amorphous; Crystallization inhibition; Dissolution; Felodipine; Indomethacin; Polymer; Solid dispersion; Supersaturation

Indexed keywords

FELODIPINE; HYDROXYPROPYLMETHYLCELLULOSE; INDOMETACIN; NANOPARTICLE; POLYMER; POVIDONE;

AMORPHOUS SOLID DISPERSION; ARTICLE; DISPERSION; DISSOLUTION; DRUG ANALYSIS; DRUG SOLUBILITY; LIGHT SCATTERING; PRECIPITATION; ULTRAVIOLET SPECTROSCOPY;

EID: 79958812380     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22579     Document Type: Article

References (50)

1. Hancock BC, Parks M. 2000. What is the true solubility advantage for amorphous pharmaceuticals? Pharm Res 17(4):397-404.
2. Konno H, Handa T, Alonzo DE, Taylor LS. 2008. Effect of polymer type on the dissolution profile of amorphous solid dispersions containing felodipine. Eur J Pharm Biopharm 70(2):493-499.
3. Leuner C, Dressman J. 2000. Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm 50(1):47-60.
4. Simonelli AP, Mehta SC, Higuchi WI. 1969. Dissolution rates of high energy polyvinylpyrrolidone (pvp)-sulfathiazole coprecipitates. J Pharm Sci 58(5):538-549.
5. Chen Y, Zhang GGZ, Neilly J, Marsh K, Mawhinney D, Sanzgiri YD. 2004. Enhancing the bioavailability of ABT-963 using solid dispersion containing Pluronic F-68. Int J Pharm 286(1-2):69-80.
6. DiNunzio JC, Miller DA, Yang W, McGinity JW, Williams RO. 2008. Amorphous cmpositions using concentration enhancing polymers for improved bioavailability of itraconazole. Mol Pharm 5(6):968-980.
7. Kennedy M, Hu J, Gao P, Li L, Ali-Reynolds A, Chal B, Gupta V, Ma C, Mahajan N, Akrami A, Surapaneni S. 2008. Enhanced bioavailability of a poorly soluble VR1 antagonist using an amorphous solid dispersion approach: A case study. Mol Pharm 5(6):981-993.
8. Law D, Schmitt EA, Marsh KC, Everitt EA, Wang WL, Fort JJ, Krill SL, Qiu YH. 2004. Ritonavir-PEG 8000 amorphous solid dispersions: In vitro and in vivo evaluations. J Pharm Sci 93(3):563-570.
9. Vaughn JM, McConville JT, Crisp MT, Johnston KP, Williams RO. 2006. Supersaturation produces high bioavailability of amorphous danazol particles formed by evaporative precipitation into aqueous solution and spray freezing into liquid technologies. Drug Dev Ind Pharm 32(5):559-567.
10. Alonzo DE, Zhang GGZ, Zhou DL, Gao Y, Taylor LS. 2010. Understanding the behavior of amorphous pharmaceutical systems during dissolution. Pharm Res 27(4):608-618.
11. Murdande SB, Pikal MJ, Shanker RM, Bogner RH. 2009. Solubility advantage of amorphous pharmaceuticals: I. A Thermodynamic analysis. J Pharm Sci 99(3):1254-1264.
12. Murdande SB, Pikal MJ, Shanker R, Bogner RH. 2011. Aqueous solubility of crystalline and amorphous drugs: Challenges in measurement. Pharm Dev Technol. 16(3):187-200.
13. Hoffman JD. 1958. Thermodynamic driving force in nucleation and growth processes. J Chem Phys 29(5):1192-1193.
14. Marsac PJ, Konno H, Taylor LS. 2006. A comparison of the physical stability of amorphous felodipine and nifedipine systems. Pharm Res 23(10):2306-2316.
15. Matteucci ME, Miller MA, Williams RO, Johnston KP. 2008. Highly supersaturated solutions of amorphous drugs approaching predictions from configurational thermodynamic properties. J Phys Chem B 112(51):16675-16681.
16. Verreck G, Six K, Van den Mooter G, Baert L, Peeters J, Brewster ME. 2003. Characterization of solid dispersions of itraconazole and hydroxypropylmethylcellulose prepared by melt extrusion-Part I. Int J Pharm 251(1-2):165-174.
17. Craig DQM. 2002. The mechanisms of drug release from solid dispersions in water-soluble polymers. Int J Pharm 231(2):131-144.
18. Serajuddin ATM. 1999. Solid dispersion of poorly water-soluble drugs: Early promises, subsequent problems, and recent breakthroughs. J Pharm Sci 88(10):1058-1066.
19. Gupta P, Kakumanu VK, Bansal AK. 2004. Stability and solubility of celecoxib-PVP amorphous dispersions: A molecular perspective. Pharm Res 21(10):1762-1769.
20. Patel R, Patel M. 2008. Preparation, characterization, and dissolution behavior of a solid dispersion of Simvastatin with polyethylene glycol 4000 and polyvinylpyrrolidone K30. J Dispersion Sci Technol 29:193-204.
21. Konno H, Taylor LS. 2006. Influence of different polymers on the crystallization tendency of molecularly dispersed amorphous felodipine. J Pharm Sci 95(12):2692-2705.
22. Yoshioka M, Hancock BC, Zografi G. 1995. Inhibition of indomethacin crystallization in poly(vinylpyrrolidone) coprecipitates. J Pharm Sci 84(8):983-986.
23. Taylor LS, Zografi G. 1997. Spectroscopic characterization of interactions between PVP and indomethacin in amorphous molecular dispersions. Pharm Res 14(12):1691-1698.
24. Wijmans JG, Baker RW. 1995. The solution-diffusion model-A review. J Membrane Sci 107(1-2):1-21.
25. Holzgrabe U. 2010. Quantitative NMR spectroscopy in pharmaceutical applications. Prog Nucl Magn Reson Spectrosc 57(2):229-240.
26. Corrigan OI, Farvar MA, Higuchi WI. 1980. Drug membrane-transport enhancement using high-energy drug polyvinylpyrrolidone (pvp) co-precipitates. Int J Pharm 5(3):229-238.
27. Hasegawa A, Taguchi M, Suzuki R, Miyata T, Nakagawa H, Sugimoto I. 1988. Supersaturation mechanism of drugs from solid dispersions with enteric coating agents. Chem Pharm Bull 36(12):4941-4950.
28. Doherty C, York P. 1987. Mechanisms of dissolution of frusemide PVP solid dispersions. Int J Pharm 34(3):197-205.
29. Simonelli AP, Mehta SC, Higuchi WI. 1976. Dissolution rates of high-energy sulfathiazole-povidone coprecipitates.2. Characterization of form of drug controlling its dissolution rate via solubility studies. J Pharm Sci 65(3):355-361.
30. Bynum K, Roinestad K, Kassis A, Pocreva J, Gehrlein L, Cheng FPP. 2001. Analytical performance of a fiber optic probe dissolution system. Dissolution Technol 8(4):1-10.
31. Liu L, Fitzgerald G, Embry M, Cantu R, Pack B. 2008. Technical evaluation of a fiber-optic probe dissolution system. Dissolution Technol 15(1):10-20.
32. Mirza T, Liu Q, Vivilecchia R, Joshi Y. 2009. Comprehensive validation scheme for in situ fiber optics dissolution method for pharmaceutical drug product testing. J Pharm Sci 98(3):1086-1094.
33. Schatz C, Ulmschneider M, Altermatt R, Marrer S, Altorfer H. 2001. Thoughts on fiber optics in dissolution testing. Dissolution Technol 8(2):1-5.
34. Bohren CF, Huffman DR. 1983. Absorption and scattering of light by small particles. 1st ed. New York: John Wiley & Sons.
35. van Eerdenbrugh B, Alonzo DE, Taylor LS. 2011. Influence of particle size on the ultraviolet spectrum of particulate-containing solutions-Implications for in-situ concentration monitoring using UV/Vis fiber-optic probes. Pharm Res. DOI: 10.1007/s11095-011-0399-4.
36. Alonzo DE. 2010. Maximizing the solubility advantage of amorphous pharmaceutical systems. Industrial and physical pharmacy. West Lafyayette: Purdue University, pp 168.
37. Corrigan OI. 1985. Mechanisms of dissolution of fast release solid dispersions. Drug Dev Ind Pharm 11(2-3):697-724.
38. Corrigan OI. 1986. Retardation of polymeric carrier dissolution by dispersed drugs-Factors influencing the dissolution of solid dispersions containing polyethylene glycols. Drug Dev Ind Pharm 12(11-13):1777-1793.
39. Corrigan OI, Stanley CT. 1982. Mechanism of drug dissolution rate enhancement from beta-cyclodextrin-drug systems. J Pharm Pharmacol 34(10):621-626.
40. Thompson CV, Spaepen F. 1979. Approximation of the free-energy change on crystallization. Acta Metallurgica 27(12):1855-1859.
41. Marsac P, Li T, Taylor L. 2009. Estimation of drug-polymer miscibility and solubility in amorphous solid dispersions using experimentally determined interaction parameters. Pharm Res 26(1):139-151.
42. Tao J, Sun Y, Zhang GGZ, Yu L. 2009. Solubility of small-molecule crystals in polymers: d-Mannitol in PVP, indomethacin in PVP/VA, and nifedipine in PVP/VA. Pharm Res 26(4):855-864.
43. Marsac PJ, Shamblin SL, Taylor LS. 2006. Theoretical and practical approaches for prediction of drug-polymer miscibility and solubility. Pharm Res 23(10):2417-2426.
44. Nordstrom FL, Rasmuson AC. 2008. Determination of the activity of a molecular solute in saturated solution. J Chem Thermodyn 40(12):1684-1692.
45. Flory PJ. 1953. Principles of polymer chemistry. 1st ed. Ithaca, New York: Cornell University Press.
46. Rajagopalan R, Hiemenz PC. 1997. Principals of colloid and surface chemistry. 3rd ed.Boca Raton: Taylor & Francis Group, LLC.
47. Zhang J, Zografi G. 2001. Water vapor absorption into amorphous sucrose-poly(vinyl pyrrolidone) and trehalose-poly(vinyl pyrrolidone) mixtures. J Pharm Sci 90(9):1375-1385.
48. Csaki KF, Nagy M, Csempesz F. 2005. Influence of the chain composition on the thermodynamic properties of binary and ternary polymer solutions. Langmuir 21(2):761-766.
49. Sabzi F, Boushehri A. 2006. Compatibility of polymer blends. I. Copolymers with organic solvents. J Appl Polym Sci 101(1):492-498.
50. Rumondor ACF, Konno H, Marsac PJ, Taylor LS. Analysis of the moisture sorption behavior of amorphous drug-polymer blends. J Appl Polym Sci 117(2):1055-1063.